Camilo de la
Fuente-Sandoval1, Pablo L. Ortiz2, Xiangling Mao3,
Patricia Alavarado-Alanis4, Oscar Rodrguez-Mayoral5,
Francisco Reyes-Madrigal4, Ariel Graff-Guerrero6,
Rodolfo Solis-Vivanco7, Rafael Favila8, Dikoma C.
Shungu3
1Neuropsychiatry
& Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologa
y Neurociruga (INNN), Mexico City, Distrito Federal, Mexico; 2Education,
INNN, Mexico City, Distrito Federal, Mexico; 3Radiology, Weill
Cornell Medical College, New York, NY, United States; 4Laboratory
of Experimental Psychiatry, INNN, Mexico City, Distrito Federal, Mexico; 5Early
Psychosis Intervention, Hospital Fray Bernardino Alvarez, Mexico City,
Distrito Federal, Mexico; 6Multimodal Neuroimaging Schizophrenia
Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; 7Laboratory
of Neuropsychology, INNN, Mexico City, Distrito Federal, Mexico; 8MR
Advanced Applications, GE Healthcare, Mexico City, Distrito Federal, Mexico
In the present study, 1H MRS was used to investigate potential dysregulations of GABA and glutamatergic compounds in subjects at ultra-high risk (UHR) for schizophrenia compared to healthy controls, and found higher levels of both neurotransmitters in the striatum and medial prefrontal cortex of the UHR group.